Klaus Edvardsen, an experienced oncology executive, has been appointed chief development officer at CureVac NV, effective 1 August 2021. He will be joining from Merck KGaA where he has led early and late-stage global oncology development. Prior to this, he was responsible for the overall development strategy for oncology and haematology at AstraZeneca Plc. Dr Edvardsen has also held leadership positions at GlaxoSmithKline Plc and at Genmab A/S. He holds a MD degree as well as a PhD in cancer biology from the University of Copenhagen in Denmark.
CureVac announced the appointment on 2 June 2021.
Copyright 2021 Evernow Publishing Ltd